Researchers in US report promising new Alzheimer's drug | Inquirer Technology

Researchers in US report promising new Alzheimer’s drug

/ 08:09 AM November 03, 2016

WASHINGTON, United States – A new experimental treatment against Alzheimer’s has proved to be promising and free of harmful side effects, researchers in the United States reported Wednesday.

The research published in the journal Science Translational Medicine on the basis of a small 32-person sample gave rise to two broader clinical trials that are now underway with more than 3,000 subjects.

The treatment uses a compound called verubecestat, developed by US pharmaceutical firm. It reduces levels of proteins called beta amyloids by blocking an enzyme known as BACE1.

Article continues after this advertisement

In people with Alzheimer’s disease, the proteins clump into plaques that damage the brain, affecting cognitive abilities, especially memory. The enzyme plays a key role in production of the proteins.

FEATURED STORIES

The 32 people who participated in the first clinical trial had been diagnosed with mild to moderate Alzheimer’s.

Pharmaceutical labs are working to develop compounds that can stop or even reverse the formation of these plaques.

Article continues after this advertisement

Until now, products developed to neutralize the BACEI enzyme had very toxic side effects, such as liver damage or further neuro-degeneration.

Article continues after this advertisement

But verubecestat does not, said Dr Matthew Kennedy of the Merck research lab in northeastern state of New Jersey.

Article continues after this advertisement

Researchers found that one or two doses of the compound were enough to lower protein levels without causing side effects.

The two so-called phase 3 clinical trials now under way to evaluate how well verubecestat works will conclude in July 2017.

Article continues after this advertisement

If the results are good, the compound could be marketed as a pill in two or three years.

READ: In the know: Alzheimer’s disease

The number of people in the United States suffering from mind-wasting Alzheimer’s could surpass 28 million by 2050 after the entire baby boomer generation gets past age 80, according to projections.

The World Health Organization says 36 million people around the world suffer from some form of dementia, most of them with Alzheimer.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

The figure is expected to double by 2030 to exceed 65.7 million, and triple by 2050 to 115.4 million, if no effective treatment is found in the next few years.

READ: Report: Nearly 47 million people now have dementia

TOPICS: Alzheimer, drug, Health, Research, US
TAGS: Alzheimer, drug, Health, Research, US

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.